Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lapatinib and/or Metformin with Hormonal Therapy in Metastatic Breast Cancer
NCT01477060Phase 2Terminated
- Sponsor
- Michelangelo Foundation
- Start
- Nov 2011
- Primary completion
- Dec 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in breast cancer comparing Lapatinib + Hormonal, Metformin + Hormonal and Lapatinib + Metformin + Hormonal (3 arms). Primary endpoint: Rate of patients free from disease progression at 3 months. Started Nov 2011; status: terminated.
02
Drugs
lapatinibmetformin
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT01477060.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01477060.